SCMP on NASDAQ

Sucampo Pharmaceuticals

Defunct pharmaceutical company

Sucampo Pharmaceuticals, Inc. was a pharmaceutical company headquartered in Rockville, Maryland that focused on gastroenterology, ophthalmology, and oncology-related disorders.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

1996Founded1

Compare with another stock.

  • TickerSCMP on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersRockville1
  • Websitewww.sucampo.com
  • Legal formDelaware corporation1
  • Business address805 King Farm Boulevard, Suite 550, Rockville, Md 208505
  • Filer categoryAccelerated filer5
  • LEI549300YPLK5FSJFMAH244
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O Corporation Service Company, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 46305064

See how the biggest companies compare on our leaderboards

Sucampo Pharmaceuticals, Inc. was a pharmaceutical company headquartered in Rockville, Maryland that focused on gastroenterology, ophthalmology, and oncology-related disorders. In 2018, the company was acquired by Mallinckrodt.3

The story

Founded by Sachiko Kunō in 1996.1

The company was founded by Ryuji Ueno and Sachiko Kuno in 1996.

In January 2006, the company received approval from the Food and Drug Administration for Amitiza.

In 2010, the company entered into arbitration with its partner, Takeda Pharmaceutical Company, claiming that sales of Amitiza floundered because of a half-hearted marketing effort by Takeda. Sucampo lost the arbitration.

In late 2015, the company moved its headquarters from Bethesda, Maryland to Rockville, Maryland.

In January 2016, the company acquired an option for an exclusive license to a drug to treat familial adenomatous polyposis.

In April 2017, the company acquired Vtesse.

In February 2018, the company was acquired by Mallinckrodt. At that time, the founders owned a combined 30% of the company.

From Wikipedia’s article on Sucampo Pharmaceuticals, shared under CC BY-SA 4.0.6

Leadership

Who has led Sucampo Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ryuji Ueno2007–2014
  2. Peter Greenleaf2014–2018

President

  1. Stanley G. Miele2010–2015

Chief financial officer

  1. Ronald W. Kaiser2007
  2. Cary J. Claiborne2011–2014
  3. Andrew P. Smith2015–2017
  4. Peter P. Pfreundschuh2017–2018
200020052010201520202025
Board members and other officers (37)

Products and brands

  • lubiprostone

Listed on Wikidata.1

Subsidiaries and ownership

Subsidiaries

From Wikidata.1

Timeline

  1. Feb 12, 2018Dissolved Dissolved1
  2. Mar 5, 2014New chief executive Peter Greenleaf becomes CEO7
  3. Aug 2, 2007New chief executive Ryuji Ueno becomes CEO8
  4. 1996Founded Founded1

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48